{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-23-004228","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2023-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.921494+00:00","generated_at":"2026-06-14T07:47:55.128162+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"VolitionRx prices $16.5M public offering of 13M shares at $1.27 per share","bullets":["Gross proceeds of $16.5M from 13M shares at $1.27/share; net proceeds ~$15.4M.","Underwriters granted 30-day option to buy up to 1.95M additional shares at same price.","Net proceeds for R&D, clinical studies, commercialization, working capital, and possible M&A.","Underwriter warrants issued to buy up to 448,500 shares at $2.00/share, exercisable after 6 months.","Offering expected to close on June 5, 2023, subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-23-004228","json":"https://secwatch.observer/filing/0001477932-23-004228.json","markdown":"https://secwatch.observer/filing/0001477932-23-004228.md","text":"https://secwatch.observer/filing/0001477932-23-004228.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793223004228/0001477932-23-004228-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793223004228/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T07:47:55.128162+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"73dd1f1e2c1439c34e91ecfd97995de84b845806","claim":"VOLITIONRX LTD entered into Underwriting Agreement with Prime Executions, Inc., doing business as Freedom Capital Markets valued at approximately $15.4 million (effective 2023-06-01).","evidence_excerpt":"On June 1, 2023, VolitionRx Limited (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Prime Executions, Inc., doing business as Freedom Capital Markets (“Freedom”), as representative of the underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 13,000,000 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), to the Underwriters.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/93314/000147793223004228/0001477932-23-004228-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Prime Executions, Inc., doing business as Freedom Capital Markets"},{"label":"Value","value":"approximately $15.4 million"},{"label":"Effective","value":"2023-06-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}